The Evolving Newborn Screening Landscape

Summary

On August 21, Avalere policy experts published a piece on the Health Affairs blog highlighting the impact of advancements in treatment and screening technology on the newborn screening landscape.

Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.

Newborn screening (NBS), the process of collecting and testing specimen samples from infants shortly after birth, is statutorily required by all 50 states and DC. Each year, up to 5,000 infants test positive for a condition through NBS, which provides an opportunity for early identification of conditions that would otherwise go undetected. State NBS programs have grown rapidly over the last decade, facilitated by advancements in treatment and screening technology. As these advancements make it possible to expand NBS programs, states will face infrastructural challenges that require system adaptation.

In “As Advancements in Treatment Drive a Newborn Screening Evolution, Will States and the Federal Government Be Able to Keep Up?” Avalere experts discuss the following:

State and federal roles in NBS policy
Factors considered by NBS decision makers
The impact of advancements in treatment and screening technology on the NBS landscape
State-level barriers to adopting new screening requirements
The Newborn Screening Saves Live Reauthorization Act that is currently under consideration in the Senate

Read the full piece on the Health Affairs blog. To receive Avalere updates, connect with us.